INTRODUCTION
We identified the phenotype of human B1 cells as CD20 The ability of the immune system to reign in the inflammatory response and limit it to an appropriate level is critical to addressing potential immunemediated damage. Failure to adequately regulate immune system activity is implicated in multiple clinical situations, including inflammatory bowel disease, respiratory asthma, food allergies, autoimmune diseases and transplant rejection. Elucidation of the cells responsible for immune regulation is expected to be invaluable in advancing the understanding of these and other diseases.
Recent work has led to the recognition that certain B cells can be regulatory in nature (Breg) and can suppress inflammatory and autoreactive responses (3). It is conceivable, then, that the current broad B-cell depletion therapies being used therapeutically could erode an important B cell-derived modulatory influence. Thus, it is of great importance to understand how to recognize Breg cells so that their number can be monitored and their fate can be determined. Immune regulation by B cells has been attributed to production and secretion of IL-10, and it has long been known that IL-10 is produced by murine B-1 cells (4, 5 (5, 7, 8) . It is notable that these reports involve the use of stimulatory regimens before assessment of IL-10 content, which could induce secretion in B cells that were not previously secreting spontaneously (5) . Moreover, the majority of the putative B-cell populations possessing B regulatory 
MATERIALS AND METHODS

Donors and Samples
Adult peripheral blood samples were obtained by venipuncture of adult volunteers after obtaining informed consent in accordance with the Declaration of Helsinki. Additional samples in the form of leukopacks were obtained from the New York Blood Center on the day of donation. This study was approved by, and all samples were obtained in accordance with, the Institutional Review Board of the North Shore-LIJ Health System.
Processing
All blood samples were treated in a similar manner and processed promptly on receipt. Mononuclear cells were obtained by density gradient separation using lymphocyte separation medium (Cellgro, Manassas, VA, USA). Except as otherwise noted, mononuclear cells were then washed and resuspended in RPMI 1640 (Cellgro) containing 10% fetal calf serum plus 2 mmol/L L-glutamine, 10 mmol/L HEPES (pH 7.25), 100 U/mL penicillin and 100 μg/mL streptomycin.
B-Cell Enrichment
For some experiments, B cells were enriched by CD19 + selection using the 
Enzyme-Linked Immunosorbent Assay
B cells were cultured in RPMI medium for 5 d, after which supernatant fluid was assayed for IL-10 by enzyme-linked immunosorbent assay (ELISA; BD Biosciences) according to the manufacturer's directions.
T-Cell Activation Assays
Sort-purified CD19-enriched B cells were cocultured with negatively selected CD4 + T cells (STEMCELL Technologies
Inc.), 1:1 in 100 μL RPMI medium (1, 2) in the presence of plate-bound anti-CD3 monoclonal antibody (0.5 μg/mL) for 72 h. T-cell expression of tumor necrosis factor (TNF)-α was assessed by intracellular staining after treatment with phorbol myristate acetate (PMA) and ionomycin plus Golgi-stop for the last 6 h. IL-10 neutralization experiments were performed by preincubating B cells with IL-10 neutralizing antibody for 30 min before introduction of B cells into the T-cell coculture.
Reagents
Anti-CD20-V450, anti-CD27-APC, anti-CD43-FITC, anti-CD11b-PE and antiCD11b-PerCP, anti-CD3-PE, anti-CD19-PE-Cy7, anti-CD4-PerCP-Cy5.5, anti-TNF-α-APC and anti-CD24-PE were obtained from BD Biosciences, along with MsIgG 1 κ isotype controls conjugated to V450, APC, FITC, PE and PerCP-Cy5.5, plus MsIgG 2a κ isotype controls conjugated to PE and PerCP. Anti-IL-10 eFluor 450 was obtained from eBiosciences. IL-10 neutralizing antibody was obtained from R&D Systems (Minneapolis, MN, USA).
Statistics
Statistical analysis was performed using Prism Software, version 5.0d, for Mac (Graphpad Software Inc., La Jolla, CA, USA). Data are displayed when appropriate as mean plus or minus the standard error of the mean (SEM). Data were compared for statistically relevant differences by using Student's t test with two-tailed analysis. P values are shown in relevant figures.
RESULTS
We evaluated spontaneous B-cell IL-10 production by combined surface and intracellular immunofluorescent staining of fixed and permeabilized, unstimulated human peripheral blood B cells. We studied CD20 + B cells to avoid CD19 We evaluated the expression of surface antigens reported here (CD19, CD20, CD27, CD43, CD11b) and elsewhere (CD19, CD20, CD24, CD27, CD38) to identify IL-10-producing B cells ( Figure 5) suggested elsewhere (7, 8) . It is important to note that, in these latter studies, B cells were stimulated with PMA plus ionomycin for 5-6 h before assay, and in some cases, with additional regimens for longer periods of time. Inasmuch as B cells would not be exposed to PMA or ionomycin in vivo, examination of B cells thus stimulated may be difficult to translate into what is actually occurring in vivo. Our approach differs in that B cells were unstimulated and IL-10 expression was, as far as can be determined, truly spontaneous. This work furthers the understanding of how effector functions of the immune system can be regulated by B cells in general and by B1 cells in particular.
O R C H E S T R A T O R B 1 C E L L S S E C R E T E I M M U N O S U P P R E S S I V E I L -
Our results indicate that IL-10 is associated with a distinct identified B-cell subset in the human system that expresses CD20, CD27, CD43 and CD11b (CD11b (14) . Further, lower levels of IL-10 and IL-10 gene polymorphisms appear to correlate with disease severity in asthma and α 1 -antitrypsin deficiency as well as other allergic conditions (15, 16) . Moreover, inflammatory conditions affecting the gut, such as Crohn's disease and inflammatory bowel disease, are associated with defects in immune regulation and IL-10 in particular (17, 18) . From the therapeutic standpoint, it is critically important to discern the identity and role of regulatory B cells in patients with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosis, psoriasis and Sjögren's Syndrome who undergo treatment with B-cell depletion therapy, lest beneficial modulatory B cells be removed along with pathogenic B cells. Thus, understanding the origin of immunoregulatory IL-10 and determining the role of regulatory B cells are key issues for clinical medicine.
CONCLUSION
Previous work showed that human B1 cells are divided on the basis of surface CD11b expression and demonstrated that CD11b + B1 cells drive T-cell proliferation due, at least in part, to elevated expression of the costimulatory molecule CD86. Here we show that this same CD11b + B1 cell population secretes IL-10 and suppresses CD3-mediated T-cell activation. In view of the capacity of CD11b + B1 cells to stimulate T-cell proliferation and to modulate T-cell activation, these B1 cells appear capable of orchestrating aspects of immune responsiveness. We propose that CD11b + B1 cells that directly affect T-cell activation and proliferation be termed "orchestrator B1 cells," or "B1orc," and that CD11b -B1 cells, which spontaneously secrete antibody but have little effect on T cells, be termed "secretor B1 cells" or "B1sec."
